Global HDAC Inhibitors Market 2023 to 2027: High Prevalence of Oncology Indications and Development of Novel Drug Delivery Systems and Combination Therapies Drives Growth


Dublin, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The "Global HDAC Inhibitors Market 2023-2027" report has been added to ResearchAndMarkets.com's offering.

The HDAC (histone deacetylase) inhibitors market is forecasted to grow by $172.61 million during 2022-2027, accelerating at a CAGR of 7.73% during the forecast period.

Companies Mentioned:

  • Acrotech Biopharma Inc.
  • AstraZeneca Plc
  • Bio Techne Corp.
  • BioVision Inc.
  • Bristol Myers Squibb Co.
  • Celleron Therapeutics Ltd.
  • Curis Inc.
  • Huya Bioscience International LLC
  • InvivoGen Corp.
  • Italfarmaco Spa
  • Medivir AB
  • Merck and Co. Inc.
  • Novartis AG
  • Onxeo SA
  • Shenzhen Chipscreen Biotechnology Co. Ltd.
  • Syndax Pharmaceuticals Inc.
  • Tokyo Chemical Industry Co. Ltd.
  • Viracta Therapeutics Inc.
  • Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
  • Cetya Therapeutics Inc.

The report on the HDAC (histone deacetylase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.

The market is driven by high target affinity and specificity, high prevalence of oncology indications, and development of novel drug delivery systems and combination therapies.

The HDAC (histone deacetylase) inhibitors market is segmented as below:

By Route Of Administration

  • Oral HDAC inhibitors
  • Parenteral HDAC inhibitors

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the growing geriatric population as one of the prime reasons driving the HDAC (histone deacetylase) inhibitors market growth during the next few years. Also, research grants and funding and growing awareness about cancer will lead to sizable demand in the market.

The report on the HDAC (histone deacetylase) inhibitors market covers the following areas:

  • HDAC (histone deacetylase) inhibitors market sizing
  • HDAC (histone deacetylase) inhibitors market forecast
  • HDAC (histone deacetylase) inhibitors market industry analysis

Key Topics Covered:

1 Executive Summary
1.1 Market overview

2 Market Landscape
2.1 Market ecosystem

3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027

4 Historic Market Size
4.1 Global HDAC (histone deacetylase) inhibitors market 2017 - 2021
4.2 Route of administration Segment Analysis 2017 - 2021
4.3 Distribution Channel Segment Analysis 2017 - 2021
4.4 Geography Segment Analysis 2017 - 2021
4.5 Country Segment Analysis 2017 - 2021

5 Five Forces Analysis

6 Market Segmentation by Route of Administration

7 Market Segmentation by Distribution Channel

8 Customer Landscape
8.1 Customer landscape overview

9 Geographic Landscape

10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
10.4 Market trends

11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks

12 Vendor Analysis

13 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/1n8pbf-hdac?w=12

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Coordonnées